- Home
- CELU vs OTLK Comparison
CELU vs OTLK Comparison
Compare CELU & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- OTLK
- Stock Information
- Founded
- CELU 2016
- OTLK 2010
- Country
- CELU United States
- OTLK United States
- Employees
- CELU N/A
- OTLK 23
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CELU Health Care
- OTLK Health Care
- Exchange
- CELU Nasdaq
- OTLK Nasdaq
- Market Cap
- CELU 42.2M
- OTLK 38.7M
- IPO Year
- CELU N/A
- OTLK 2016
- Fundamental
- Price
- CELU $1.37
- OTLK $1.15
- Analyst Decision
- CELU
- OTLK Strong Buy
- Analyst Count
- CELU 0
- OTLK 5
- Target Price
- CELU N/A
- OTLK $10.20
- AVG Volume (30 Days)
- CELU 97.9K
- OTLK 358.2K
- Earning Date
- CELU 12-06-2024
- OTLK 05-14-2025
- Dividend Yield
- CELU N/A
- OTLK N/A
- EPS Growth
- CELU N/A
- OTLK N/A
- EPS
- CELU N/A
- OTLK N/A
- Revenue
- CELU $48,200,000.00
- OTLK N/A
- Revenue This Year
- CELU N/A
- OTLK N/A
- Revenue Next Year
- CELU $233.89
- OTLK $288.46
- P/E Ratio
- CELU N/A
- OTLK N/A
- Revenue Growth
- CELU 225.94
- OTLK N/A
- 52 Week Low
- CELU $1.00
- OTLK $0.87
- 52 Week High
- CELU $5.69
- OTLK $9.98
- Technical
- Relative Strength Index (RSI)
- CELU 40.70
- OTLK 31.92
- Support Level
- CELU $1.64
- OTLK $1.15
- Resistance Level
- CELU $2.40
- OTLK $1.31
- Average True Range (ATR)
- CELU 0.20
- OTLK 0.12
- MACD
- CELU -0.02
- OTLK -0.02
- Stochastic Oscillator
- CELU 0.00
- OTLK 6.79
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.